Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Leqvio. Always confirm against the full prescribing information.
100 interactions
Abacavir
Abacavir may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Abatacept
Abatacept may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Abemaciclib
Abemaciclib may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Abiraterone
Abiraterone may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Acamprosate
Acamprosate may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Acarbose
Acarbose may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Acebutolol
Acebutolol may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Aceclofenac
Aceclofenac may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Acetaminophen
Acetaminophen may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Acetazolamide
Acetazolamide may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Acetylsalicylic acid
Acetylsalicylic acid may increase the hepatotoxic activities of Inclisiran.
Level 2 evidence
Acitretin
Acitretin may increase the hepatotoxic activities of Inclisiran.
Leqvio (Inclisiran) has 488 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Leqvio (Inclisiran) has 1 major, 0 moderate, and 487 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Leqvio. Always confirm against the full prescribing information.